Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132403 | 0.90 | NT5E (0.37) | ALDH1A1NT5EADRB2ADRA2AHTR2C | |
| SCHEMBL13815267 | 0.80 | PDE3B (0.39) | ALDH1A1NT5EADRB2ADRA2AHTR2C | |
| SCHEMBL16132384 | 0.79 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL13666781 | 0.72 | ALDH1A1 (0.36) | ALDH1A1ADRB2ADRA2AHTR2CAXL | |
| SCHEMBL24967231 | 0.71 | — | — | |
| SCHEMBL16132464 | 0.70 | NT5E (0.40) | ALDH1A1NT5EADRB2ADRA2AHTR2C | |
| SCHEMBL10163487 | 0.68 | NT5E (0.45) | ALDH1A1NT5EADRB2ADRA2AHTR2C | |
| SCHEMBL18554787 | 0.67 | NOS3 (0.35) | — | |
| SCHEMBL16132313 | 0.67 | MAPT (0.54) | ALDH1A1 | |
| SCHEMBL18611211 | 0.65 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ALDH1A1 3927/4885NT5E 4848/4885ADRB2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.